Abstract

CORTES MORALES, Benjamín. Metabolic syndrome and second generation antipsychotic agents. Rev. Asoc. Esp. Neuropsiq. [online]. 2011, vol.31, n.2, pp.303-320. ISSN 2340-2733.  https://dx.doi.org/10.4321/S0211-57352011000200009.

Although some second generation antipsychotic agents reduce the risk of extra-pyramidal adverse effects against first generation agents, they have been associated to an increased incidence of metabolic syndrome. This syndrome is characterized by insulin resistance, abdominal obesity, atherogenic dyslipidemia (hypertriglyceridemia, decrease of HDL-cholesterol/ LDL-cholesterol ratio), arterial hypertension and a prothrombotic and proinflammatory state. Metabolic syndrome increases significantly the risk of cardiovascular illness and premature death. Therefore, a multidisciplinary approach to that syndorme's prevention and treatment could result in a substantially impact upon the general state of patients meetings its criteria. We emphasize current physiopathological findings, increased risk with polytherapy (second generation antipsychotics and both second and first generation combination), current diagnostic criteria and monitoring of patients at risk. Our aim is to contribute to an early detection that possibilities implementation of pharmacological and non pharmacological multidisciplinary interventions.

Keywords : Antipsychotic Agents; Metabolic Syndrome; Cardiovascular Disease; Insulin Resistance; Obesity.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )